Scholar Rock to Present at Cowen’s 42nd Annual Health Care Conference

Rhea-AI Summary

Scholar Rock (NASDAQ: SRRK) has announced its participation in an Orphan Neuro and Neuromuscular panel discussion at Cowen’s 42nd Annual Health Care Conference on March 7, 2022, at 9:10 a.m. ET. The event will be accessible via live webcast, with a replay available for 30 days thereafter. Scholar Rock focuses on developing innovative therapies targeting serious diseases influenced by protein growth factors. Its proprietary platform allows for the creation of monoclonal antibodies that selectively target signaling proteins in the disease microenvironment.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will participate in an Orphan Neuro and Neuromuscular panel discussion at Cowen’s 42^nd Annual Health Care Conference on Monday, March 7, 2022 at 9:10 a.m. ET.

A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com. An archived replay of the webcast will be available on the Company’s website for approximately 30 days following the presentation.

About Scholar Rock

Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. Scholar Rock’s approach to targeting the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path. For more information, please visit www.ScholarRock.com or follow Scholar Rock on Twitter (@ScholarRock) and LinkedIn (https://www.linkedin.com/company/scholar-rock/).

Scholar Rock® is a registered trademark of Scholar Rock, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220225005011/en/

Scholar Rock Contact:

Investors

Rushmie Nofsinger

Scholar Rock

rnofsinger@scholarrock.com

857-259-5573

Media

Ariane Lovell

Finn Partners

ariane.lovell@finnpartners.com

917-565-2204

Source: Scholar Rock

FAQ

When is Scholar Rock participating in the Cowen Health Care Conference?

Scholar Rock will participate in Cowen's 42nd Annual Health Care Conference on March 7, 2022, at 9:10 a.m. ET.

How can I access the Scholar Rock conference presentation?

The live webcast of Scholar Rock's presentation can be accessed via the Investors & Media section of their website.

What is the focus of Scholar Rock's research and development?

Scholar Rock specializes in developing therapies for serious diseases involving growth factors, such as neuromuscular disorders, cancer, and fibrosis.

What unique approach does Scholar Rock use in its drug development?

Scholar Rock employs a proprietary platform to create monoclonal antibodies that locally target growth factor signaling proteins.